Stifel ups Reata price target to $50

Stifel ups Reata price target to $50

Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its Cardinal study evaluating BARD in Alport chronic kidney disease (CKD). The stock closed at $37.66 on July 24.

Read More

Leerink starts Mersana at OP

Leerink starts Mersana at OP

Leerink launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with an “outperform” rating and $23 one-year price target, representing an approximate $500-million valuation. The stock closed at $14.05 on July 21.

Read More

RBC upgrades CRH Medical to OP

RBC upgrades CRH Medical to OP

RBC Capital Markets upgraded CRH Medical (TSX:CRH; NYSE MKT:CRHM) to “outperform” from “sector perform” but lowered its price target to $6 (Canadian) from $8.50. The stock closed at $4.07 on July 20.

Read More

HCW starts Agile Therapeutics at buy

HCW starts Agile Therapeutics at buy

H.C. Wainwright launched coverage of Agile Therapeutics (NASDAQ:AGRX) with a “buy” rating and $10 price target, saying the company is significantly undervalued assuming its Twirla combination hormonal contraceptive (CHC) patch can get FDA approval. The stock closed at $4.93 on July 19.

Read More

Clearside enrolls first patient in TYBEE trial

Clearside enrolls first patient in TYBEE trial

Clearside Biomedical (NASDAQ:CLSD) enrolled the first patient in the Phase 2 TYBEE clinical trial of CLS-TA for suprachoroidal administration used together with intravitreally administered EYLEA for the treatment of diabetic macular edema (DME).

Read More

Dimerix posts positive Phase 2a in CKD

Dimerix posts positive Phase 2a in CKD

Dimerix (ASX:DXB) announced positive safety and efficacy data following a 27-patient Phase 2a proof-of-concept, dose escalation study in chronic kidney disease (CKD) for lead program, DMX-200.

Read More